1. Group psychotherapy to quit tobacco smoking in adolescents 1993~1996
2. Smoking behaviour in Taiwanese adolescents 1996
3. Nicotine dependence in alcoholics 1996~1999
4. Tobacco smoking in schizophrenic patients 1999
5. Open-label olanzapine in treatment-refractory schizophrenia 1998~2000
6. Risperidone in the treatment of acutely exacerbated schizophrenia 1998~2000
7. Smoking behaviour in drug addicts 1998~2001
8. A mental health model for earthquake afflicted pupils in central Taiwan 1999~2001
9. Smoking behaviour in junior high school students 2000
10. Tobacco smoking in depressive patients 2001
11. Olanzapine plus fluoxetine combination therapy in treatment-resistant depression: A dose ranging study 1999~2001
12. The rate of hyperglycemia & diabetes of schizophrenic or schizoaffective patients treated with antipsychotics 2001
13. An international, multicentre, double-blind, randomized, placebo-controlled study of the safety and efficacy of Quetiapine Fumarate and Haloperidol as monotherapy in the treatment of acute mania 2001~2002
14. Effectiveness & Safety of olanzapine in the treatment of Taiwanese patients with schizophrenia: An observational study 2001~2002
15. A post-marketing hospitalized of the utility of venlafaxine in achieving response and maintaining remission among Taiwanese patients with depression 2002
16. The efficacy and safety of flexible dose ranges of risperidone vs placebo or haloperidol in the treatment of manic episodes associated with bipolar I disorder 2002
17. Ziprasidone intramuscular/oral versus haloperidol intramuscular/oral in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: A six week open administration study with blinded assessments 2002~2003
18. Prevalence of insomnia in various psychiatric diagnostic categories 2002~2003
19. Emergency treatment of acute psychosis with Risperidone oral solution 2002~2003
20. A clinical dose study of antipsychotics in Taiwanese schizophrenics 2002~2003
21. A placebo control, double blind, cross over study of modafinil in patients with narcolepsy 2003~2004
22. Prevalence of depressive disorders in Taiwanese adult diabetes mellitus patients 2003~2004
23. A clinical study of psoriasis comorbid depression 2003~2004
24. A comparative study to evaluate the efficacy and tolerability of zotepine versus haloperidol in combination with mood stabilizer in the treatment of hospitalized, moderate to severe mania patients 2003~2004
25. Weight-control program for schizophrenia 2003~2004
26. Survey of occupational status in female schizophrenics 2004
27. Influence factors of sex offender group psychotherapy attendance 2003~2004
28. Quetiapine in practice evaluation programme 2004~2005
29. Ziprasidone observational study of cardiac outcomes 2004-2005
30. A randomize, double-blind, placebo-controlled, parallel-group study evaluating paliperidone in the prevention of recurrence in subjects with schizophrenia 2004-2005
31. Comparative health outcome of schizophrenia outpatients treated by olanzapine and risperidone 2004-2005
32. Duloxetine versus paroxetine in the acute treatment of major depression 2004-2005
33. A double-blind, double-dummy, randomized, active-controlled study comparing the efficacy and tolerability of mirtazapine and venlafaxine XR in patients with major depressive disorder 2005
34. A genetics association study for drugs-induced parkinsonism 2005-2006
35. Open-label quetiapine pharmacotherapy in treatment-refractory schizophrenia 2005
36. A comparison of duloxetine hydrochloride, venlafaxine extended release, and placebo in the treatment of generalized anxiety disorder 2005
37. Asenapine in bipolar mania trial 2005-2006
38. Quetiapine in bipolar depression 2005-2006
39. Sleep disorders in renal dialysis patients 2005-2006
40. Quetiapine in bipolar mania 2005-2006
41. Antidepressant LTS4848 safety and tolerability trial 2005-2006
42. A Randomized Double-Blind, Active and Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated with Bipolar I Disorder 2006-2007
43. Agomelatine in Major Depressive Disorder 2006-2007
44. A Double-Blind, Randomized, Placebo-Controlled, Quetiapine-referenced, Multicenters Study of the Long-term Bifeprunox Efficacy, Safety and Tolerability in Patients with Chronic, Stable Schizophrenia 2006-2007
45. Depression, Sleep Disorder, and Smoking in Hemodialysis Patients 2006-2007
46. A 3-month Epidemiological Study to Establish Characteristics of Asian Patients with Acute Major Depressive Disorder 2006-2007
47. Health Evaluation of Aripiprazole Long-term Therapy(HEALTH) 2006-2008
48. A randomized comparison of intramuscular olanzapine, haloperidol and oral risperidone solution, oral olanzapine orodispersible tablet for acute treatment of psychotic agitation 2006-2007
49. A meaningful day program 2007-2008
50. A randomized, double-blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate in subjects with schizophrenia 2007
51. Efficacy and safety of paliperidone vs. placebo or comparator in the treatment of manic episodes associated with bipolar I disorder 2007-2008
52. A multicenter, randomized, double-blind, paroxetine-referenced, parallel-group study to evaluate the safety, efficacy, and tolerability of 3 fixed doses of desvenlafaxine succinate sustained-release tablets in adult outpatients with major depressive disorder 2007-2008
53. Evaluation of efficacy and safety of long-acting risperidone microspheres in patients with schizophrenia or schizoaffective disorders, who is receiving psychiatric home-care treatment, when switching from typical depot or oral antipsychotics to long-acting risperidone microspheres 2007-2008
54. Aripiprazole in bipolar disorder for long term effectiveness 2007-2008
55. A double-blind, randomized, parallel-group, placebo-controlled study of the safety, tolerability and efficacy following sequential dose regimens of Lu 31-130 to male patients with schizophrenia 2007-2008
56. Patient education service program 2008-2008
57. An open-label prospective trial to evaluate the tolerability, safety and maintained efficacy of a transition to Paliperidone ER in subjects with schizophrenia previously unsuccessfully treated with other oral atypical antipsychotics 2008-2009
58. A comparative study to evaluate the efficacy, adverse effects and adherence of Zoloft versus CenZoft in the treatment of major depressive disorder 2008-2009
59. Randomized, double-blind, parallel-group, placebo-controlled, and active referenced study of LUAA 34893 to evaluate the efficacy and safety of three doses of LUAA34893 and quetiapine versus placebo in the treatment of depression in patients with bipolar I or II disorder 2008-2009
60. A randomized, double-blind, placebo-controlled, cross-over study of low-dose quetiapine XR in patients with chronic treatment resistant psychophysiological insomnia 2008-2010
61. Tobacco smoking in mental illness patients 2009
62. A naturalistic observational study to evaluate efficacy of 2nd-generation antipsychotics and remission status for patients with schizophrenia/schizoaffective disorder 2009-2010
63. A Phase 2, 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia otsuka 2009-2010
64. A phase 2, multicenter, open-label study to assess the safety and tolerability of oral OPC-34712 as monotherapy in adult patients with schizophrenia 2009-2010
65. ITAREPS 2009-2010
66. Randomized, placebo-controlled, double-blind, parallel-group, confirmatory study of SM-13496 (lurasidone HCl) in patients with schizophrenia 2009
67. A 52-week , multicenter , randomized , double-blind , placebo -controlled study to evaluate the efficacy , safety , and tolerability of an intramuscular depot formulation of aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia “ASPIRE US” (Aripiprazole Intramuscular Depot Program in Schizophrenia) 2009-2010
68. Relationship between psychological craving of heroin and methadone maintain therapy 2009-2011
69. Center of excellence in relapse prevention in schizophrenia outpatients 2010
70. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the safety and efficacy of MK-4305 in patients with primary insomnia - Study A 2010-2012
71. A multicenter, randomized, double-blind study to evaluate the efficacy, safety and tolerability of an oral aripiprazole/escitalopram combination therapy in patients with major depressive disorder 2010-2012
72. A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study of paliperidone palmitate in subjects with schizophrenia 2010-2012
73. Safety, tolerability, and treatment response of paliperidone palmitate in subjects with schizophrenia when switching from oral antipsychotics 2010-2013
74. A multicenter, active-controlled, double-blind, parallel group-comparison trial to investigate the efficacy and safety of aripiprazole IM depot (OPC-14597IMD) compared with aripiprazole tablets in patients with schizophrenia 2010-2014
75. Expanding rapid ascertainment networks of schizophrenia families in Taiwan 2010-2015
76. A randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosage of LUAA 21004, in acute treatment of major depressive disorder 2011-2013
77. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with acute exacerbation of schizophrenia
78. Internet and game addiction of university students
79. Randomized, double-blind, parallel-group, placebo-controlled, confirmatory study of SM-13496(lurasidone Hcl) in patients with schizophrenia
80. Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia
81. Occupational counseling program in schizophrenia patients with long acting antipsychotic treatment
82. Taiwan Clinical Trial Consortium for Mental Disorders
83. Taiwan Clinical Trial Consortium for Mental Disorders II
84. A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of 4 orally administrated doses of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment (B.I. 1289.6 study)
85. Taiwan Clinical Trial Consortium for Mental Disorders III
86. Adverse effects of antipsychotics in psychotic patients
87. Osteoporosis and osteopenia in schizophrenics
88. Polydipsia in psychiatric patients
89. Hypersalivation in psychiatric patients
90. Taiwan Clinical Trial Consortium for Disorders IV
91. Attitudes toward substance use disorder of college students
92. Taiwan Clinical Trial Consortium for Disorders V
93. Missed appointment in psychiatric clinic
94. Harm perception of substance addiction and experience of substance use disorder in university students
95. SAGE-547 in postpartum depression
96. Taiwan Clinical Trial Consortium for Disorders VI
97. Comparison study of different antipsychotic long-acting injections
98. Attitude of schizophrenic patients towards antipsychotic long-acting injections
99. Post-marketing study of paliperidone palmitate (PP3M)
100. Clinical study of lurasidone: efficacy and acceptability
101. Clinical study of vortioxetine: efficacy and safety, and tolerability
102. Attitudes of psychiatrists to antipsychotic long-acting injections
103. Taiwan Clinical Trial Consortium for Disorders VII
104. Taiwan Clinical Trial Consortium for Disorders VIII
105. Efficacy and safety in treatment of Adjunctive lurasidone in patients with major depressive disorder
106. Correlation of TCQ and PDQ-5
107. Development and validation of a brief questionnaire for assessment of cognitive function in major depressive disorder paints
108. ESCAPE-TRD study, A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor 2011-2013